Torigen Pharmaceuticals

Torigen Pharmaceuticals is an animal health biologics company focused on developing innovative cancer therapies for companion animals. Their primary offering is an autologous cancer vaccine, a personalized immunotherapy created from a surgically resected portion of the patient's tumor tissue. This prescription product is regulated by the USDA Center of Veterinary Biologics under nine CFR 103.3.

The autologous cancer vaccine is an active immunotherapy consisting of cells harvested from the patient's own tumor. Through a patented method, the cellular material and tumor-associated antigens are preserved and mixed with immune-stimulating adjuvants. The objective is to increase activation of tumor-specific T-cells, enhancing the pet's immune system's ability to destroy cancer cells, slow tumor growth, or delay metastasis.

Torigen's autologous cancer vaccine has demonstrated promising results in treating metastatic hemangiosarcoma in dogs. A study published in December 2020 revealed a more than three-fold increase in survival compared to surgery alone, with a median survival time equivalent to dogs receiving maximum tolerated chemotherapy without reported adverse events.

In June 2022, Torigen announced a national distribution agreement with MWI Animal Health, a leading distributor of animal health products, expanding access to their autologous cancer vaccine across the US. Additionally, in April 2023, Torigen entered a Preferred Partner Agreement with Veterinary Management Groups, providing their 2,000+ member clinics access to Torigen's products and services.

Torigen is a spin-out from the University of Notre Dame, backed by prominent investors such as Werth Family Investment Associates, Connecticut Innovations, and SoGal Ventures. With over 50% of dogs over 10 dying from cancer, Torigen's mission is to provide affordable and effective cancer care solutions for all companion animals.